Investigation of Human Papillomavirus Prevalence in Women in Eskişehir, Turkey by Pap Smear, Hybrid Capture 2 Test and Consensus Real-Time Polymerase Chain Reaction and Typing with Pyrosequencing Method

IntroductionThe human papillomavirus (HPV) family is characterized by minimal genotypic differences corresponding to different virus types. The aim of this study was to detect the HPV coinfections and the inner genotype in a series of 336 cervical-vaginal samples.MethodsA total of 336 cervical-vaginal samples were taken from 2007 to 2009 using specific molecular techniques such as molecular sequencing and hybridizations. The genome amplification of the L1 open reading frame was analyzed by real-time polymerase chain reaction; direct sequencing was performed by SYBR green fluorescent molecule and degenerate primers MY09 and MY11. The HPV genotyping was accomplished via oligonucleotide probe hybridization. The phylogenetic correlations in coinfections were analyzed by sequence homology of the L1 genomic region. Identified genotypes were then compared.ResultsHuman papillomavirus positivity was observed in 125 cases (37.2%), with 21 cases (16.8%) of HPV presence in coinfections. Coinfections involved HPV 16 genotype (8 cases) and HPV 18 (5 cases). The HPV 16 infection was mainly associated with genotypes with a lower-than-broad sequence homology, so the HPV 18 was linked to genotypes represented in the opposite phylogenetic tree.ConclusionsThe combined and steady use of diagnostic procedures, such as real-time polymerase chain reaction, molecular hybridization, direct sequencing, and HPV genotyping test, allow accurate diagnosis of monoinfections and coinfections. This may faciliate the development of specific viral tests and prophylactic anti-HPV vaccines.

Download Full-text

cobas®4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens

Expert Review of Molecular Diagnostics ◽

10.1586/14737159.2014.865521 ◽

2013 ◽

Vol 14 (1) ◽

pp. 5-16 ◽

Cited By ~ 16

Author(s):

Sandra D Isidean ◽

François Coutlée ◽

Eduardo L Franco

Keyword(s):

Polymerase Chain Reaction ◽

Human Papillomavirus ◽

Real Time ◽

Polymerase Chain Reaction Assay ◽

Chain Reaction ◽

Hpv Test ◽

Polymerase Chain

Download Full-text

Validation of a New Low-Cost, Methanol-Based Fixative for Cervical Cytology and Human Papillomavirus Detection

Acta Cytologica ◽

10.1159/000489873 ◽

2018 ◽

Vol 62 (5-6) ◽

pp. 393-396 ◽

Cited By ~ 1

Author(s):

Katia Ramos Moreira Leite ◽

Thais Silva ◽

Bruna Naum ◽

Flavio Canavez ◽

Juliana Canavez ◽

...

Keyword(s):

Cervical Cancer ◽

Polymerase Chain Reaction ◽

Human Papillomavirus ◽

Low Income ◽

Pap Smear ◽

Low Cost ◽

Cervical Cytology ◽

Low Income Countries ◽

Chain Reaction ◽

Polymerase Chain

Objective: To test the performance of a new fixative for pap smear collection for liquid-based cervical cytology, CellPreserv® and compare it with the commercially available, PreservCyt® used in the diagnosis and detection of human papillomavirus (HPV). Methods: Seven hundred twenty five women participated in this study after signing an informed consent. The specimens were collected using a traditional device, agitated in PBS, and equally divided in both fixatives. The slides were prepared routinely, stained by Papanicolaou, examined blindly by 2 cytologists, and reviewed by one cytopathologist. To search for HPV, 1,000 μL from each fixative was taken and processed by polymerase chain reaction. Results: Considering the adequacy of samples, both fixatives had similar results – 0.33 and 0.32% of the cases unsatisfactory for PreservCyt® and CellPreserv®, respectively. Considering the 701 satisfactory cases and comparing the new fixative to the traditional fixative, there was 99.3% concordance between both. The results regarding the HPV detection was 100% concordant between the 2 fixatives. Conclusion: The new methanol-based fixative, CellPreserv®, is cheaper and equally efficient for treating cervical cancer screening and for HPV detection, and can be safely used by the health system prevailing in low-income countries.

Download Full-text